Crescent Capital BDC, Inc. (CCAP)
| Market Cap | 485.04M -18.1% |
| Revenue (ttm) | 167.29M -15.2% |
| Net Income | 34.51M -53.1% |
| EPS | 0.93 -53.1% |
| Shares Out | 36.97M |
| PE Ratio | 14.08 |
| Forward PE | 8.01 |
| Dividend | $1.68 (12.81%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 155,283 |
| Open | 13.49 |
| Previous Close | 13.55 |
| Day's Range | 13.12 - 13.55 |
| 52-Week Range | 11.80 - 17.02 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 15.86 (+20.88%) |
| Earnings Date | May 13, 2026 |
About CCAP
Crescent Capital BDC, Inc. is as a business development company is a private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
Financial Performance
In 2025, Crescent Capital BDC's revenue was $167.29 million, a decrease of -15.24% compared to the previous year's $197.36 million. Earnings were $34.51 million, a decrease of -53.14%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CCAP stock is "Buy." The 12-month stock price target is $15.86, which is an increase of 20.88% from the latest price.
News
Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its First Quarter Ended March 31, 2026 Financial Results
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC”) (NASDAQ: CCAP) today announced it will release its financial results for the first quarter ended March 31, 2...
Crescent Capital BDC price target lowered to $15 from $15.50 at Keefe Bruyette
Keefe Bruyette analyst Paul Johnson lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15 from $15.50 and keeps an Outperform rating on the shares. Published first on…
Crescent Capital BDC initiated with a Neutral at B. Riley
B. Riley initiated coverage of Crescent Capital BDC (CCAP) with a Neutral rating and $13.50 price target Crescent has historically compared favorably to the business development company sector on cred...
Crescent Capital BDC price target lowered to $13 from $14 at Wells Fargo
Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $14 and keeps an Equal Weight rating on the shares. The firm…
Crescent Capital BDC Earnings Call Transcript: Q4 2025
Q4 2025 net investment income was $0.45 per share, covering the dividend, with NAV per share declining to $19.10 due to unrealized losses. Portfolio remains diversified and first lien-focused, while management reviews dividend and fee structure amid lower rates.
Crescent Capital BDC, Inc. Reports Fourth Quarter 2025 Earnings Results; Declares a First Quarter Base Dividend of $0.42 Per Share
LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $1.81 per share and net income of $0.93 p...
Crescent Capital BDC, Inc. Reschedules Earnings Release and Conference Call for Fourth Quarter and Fiscal Year Ended December 31, 2025
LOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (the “Company”) (NASDAQ: CCAP) today announced that it has rescheduled the release of its financial results and accompanying e...
Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Fourth Quarter and Fiscal Year Ended December 31, 2025 Financial Results
LOS ANGELES, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC”) (NASDAQ: CCAP) today announced it will release its financial results for the fourth quarter and fiscal year e...
Crescent Capital BDC price target lowered to $16 from $16.50 at Ladenburg
Ladenburg lowered the firm’s price target on Crescent Capital BDC (CCAP) to $16 from $16.50 and keeps a Buy rating on the shares following the Q3 report. Published first on…
Crescent Capital BDC price target lowered to $19 from $20 at Oppenheimer
Oppenheimer lowered the firm’s price target on Crescent Capital BDC (CCAP) to $19 from $20 and keeps an Outperform rating on the shares following quarterly results. The firm says its…
Crescent Capital BDC price target lowered to $15.50 from $17 at Keefe Bruyette
Keefe Bruyette analyst Paul Johnson lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15.50 from $17 and keeps an Outperform rating on the shares. The risks are…
Crescent Capital BDC price target lowered to $14 from $15 at Wells Fargo
Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $14 from $15 and keeps an Equal Weight rating on the shares. The firm…
Crescent Capital BDC price target lowered to $15.50 from $16.50 at Clear Street
Clear Street analyst Mickey Schleien lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15.50 from $16.50 and keeps a Buy rating on the shares. The company reported…
Crescent Capital BDC Earnings Call Transcript: Q3 2025
Net investment income held steady at $0.46 per share, with strong dividend coverage and a stable, diversified portfolio. NAV declined due to tariff-related losses, but liquidity and capital structure remain robust, supporting continued investment and dividend stability.
Crescent Capital BDC reports Q3 EPS 46c, consensus 46c
Reports Q3 NAV per share $19.28. The company said, “As of September 30, 2025, the Company had $27.8 million in cash and cash equivalents and restricted cash and $239.8 million…
KBRA Assigns Rating to Crescent Capital BDC, Inc.'s $185 Million Senior Unsecured Notes due in 2029 and 2031
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns a rating of BBB to Crescent Capital BDC, Inc.'s (NASDAQ: CCAP or "the company") $67.5 million, 5.87% senior unsecured notes due 2029, $50 ...
Crescent Capital Group Announces Hiring of Juan Grana as Managing Director to Lead Bank Capital Solutions
LOS ANGELES & LONDON--(BUSINESS WIRE)--Crescent Capital Group LP, a leading alternative credit investment firm, announced today the hiring of Juan Grana as Managing Director to head the firm's bank ca...
Crescent Capital BDC initiated with a Buy at Clear Street
Clear Street initiated coverage of Crescent Capital BDC (CCAP) with a Buy rating and $16.50 price target The company benefits from strong origination and co-investment capabilities, the analyst tells ...
Crescent Capital BDC Earnings Call Transcript: Q2 2025
Net investment income rose to $0.46 per share ($0.48 adjusted), with strong dividend coverage and stable portfolio yields. NAV per share dipped slightly due to a special dividend, while credit quality remains robust and risk management proactive amid ongoing market volatility.
Crescent Capital BDC reports Q2 EPS 46c, consensus 47c
Reports Q2 NAV per share $19.55. The company said, “As of June 30, 2025, the Company had $26.1 million in cash and cash equivalents and restricted cash and $227.2 million…
Crescent Capital BDC announces $20M stock repurchase program
The company’s board authorized a stock repurchase program for the purpose of repurchasing up to an aggregate of $20M of its common stock in the open market at certain thresholds…
Crescent Capital BDC, Inc. Reports Second Quarter 2025 Earnings Results; Declares a Third Quarter Base Dividend of $0.42 Per Share
LOS ANGELES, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.46 per share and net income of $0.41 p...
Crescent Capital BDC upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette upgraded Crescent Capital BDC (CCAP) to Outperform from Market Perform with a $17 price target Keefe expects a stable quarter for business development company earnings results, with few...
Crescent Capital upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette upgraded Crescent Capital BDC (CCAP) to Outperform from Market Perform with an unchanged price target of $17.
Private Equity For The People: 3 High-Yield BDCs Yielding Up To 13%
Let's invest like private equity pros without needing seven figures. Yes, that's right—PE-style starting for as little as $8.